Navigation Links
The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs

Provides Protection for People with Lupus and other Chronic Diseases

WASHINGTON, Aug. 7 /PRNewswire-USNewswire/ -- The Lupus Foundation of America (LFA) President and Chief Executive Officer, Sandra C. Raymond, issued the following statement regarding S.1630 "The Affordable Access to Prescription Medications Act of 2009" introduced on Thursday, August 6, 2009 by Senator John (Jay) D. Rockefeller IV (D-WV).

"We support and applaud Senator Rockefeller for this important bill which will provide all Americans with vastly improved access to life-saving medications. The proposed legislation imposes a $200 cap on the amount a person could be charged for any one prescription, and a $500 cap on the total amount an individual could be charged for all medications during any given month. This is critical to controlling costs for people with lupus, as a past survey has shown that more than 60 percent of patients take five or more medications.

"It has been 50 years since the U.S. Food and Drug Administration approved a medication for lupus. There are several potential new treatments in the near-term pipeline that may provide a better quality of life for people with lupus. But these anticipated new treatments will mean nothing if people with lupus are not able to access them because they are cost-prohibitive. For example, some people with multiple sclerosis, another autoimmune disorder, may pay out-of-pocket in excess of $800 a month for access to new medications.

"Studies have also shown that patients will avoid filling prescriptions, skip doses, or cut pills in half because of costs. Stopping medication can lead to greater disease severity, and for people with lupus, could result in organ failure. In addition, for people with chronic conditions it can often result in hospitalization leading to greater overall health care costs for both patients and society. For patients with serious or life-threatening conditions or for an individual with multiple co-morbid conditions, this legislation will provide greater access and affordability for prescribed treatments.

"We encourage everyone to join us in supporting this important piece of legislation by contacting their Senators and asking them to sign on as a co-sponsor to the legislation. At the Lupus Foundation of America we will do our part to ensure support for this important legislation and watch with great interest as it moves through the United States Congress."

Read Official Press Release from the Office of Senator John D. Rockefeller

About Lupus

Lupus is an acute and chronic autoimmune disease in which the immune system is unbalanced, causing inflammation and tissue damage to virtually any organ in the body. Its health effects include heart attacks, strokes, seizures, miscarriages, and organ failure. Ninety percent of the people with lupus are women, and it is two to three times more common among African Americans, Hispanics/Latinos, Native Americans, and Asians. Lupus is unpredictable and potentially fatal, yet no satisfactory treatment or cure exists.

About the LFA

The LFA is the foremost national nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all people affected by lupus. Founded in 1977, the LFA has a nationwide network of nearly 300 chapters and support groups and operates programs of research, education, and advocacy.

SOURCE Lupus Foundation of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Flu Shot May Be Less Effective in Those With Lupus
2. Immune responses to flu vaccine are diminished in lupus patients
3. LFAGW to Offer First Living with Lupus Baltimore Workshop on August 15
4. Reminder - Human Genome Sciences to Host Conference Call to Discuss Top-Line Phase 3 Results for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Systemic Lupus Erythematosus
5. LFAGW to Run Could I Have Lupus? Workshop on July 26; Mystics Game Follows
6. Basic Facts and Statistics About Lupus
7. The New York Times Website Patient Voices Series Features People Affected by Lupus
8. Lupus Foundation of America Accepting Letters of Intent for Research Grants on Adult Stem Cell Research and Health-Related Quality of Life in Pediatric Lupus
9. Lupus Foundation of America Seeks Proposals for Research Studies on Childhood Lupus and Stem Cell Transplantation
10. Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients
11. Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology: